Hims and Hers tops revenue estimates as telehealth provider attracts more users

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Hims and Hers tops revenue estimates as telehealth provider attracts more users

Hims and Hers (HIMS) PT Lowered to $48 at Jefferies, 'want to see proof points of consumer traction'

November 4, 2025 8:06 AM EST

Jefferies analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $48.00 (from $51.00) while maintaining a Hold rating.

The analyst comments "HIMS delivered a solid Q3, with revs, EBITDA, & EPS beating Street ests by 3%, 15%, & 30% respectively. EBITDA margins of 13.1% beat Street... More

Needham on Hims and Hers (HIMS): 'we believe this incremental near-term investment and likely growing pains'

November 4, 2025 5:13 AM EST

Needham analyst Ryan MacDonald reiterated a Hold rating on Hims and Hers (NYSE: HIMS).

The analyst comments "We are reiterating our Hold rating on Hims & Hers Health (HIMS) following the company's earnings print in which a 3Q beat was offset... More

BTIG Hims and Hers (HIMS): 'MAHA is being Implemented through HIMS with Proactive Health'

November 4, 2025 4:35 AM EST

BTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).

The analyst comments "On Monday, 11/3/25 AMC, HIMS reported good 3Q:25 results. Revenue of $599M +49% y/y exceeded BTIG / consensus / guidance of $580.1M / $580M / $570M-$590M and adjusted EBITDA of $78.4M +53% y/y also came in well ahead of BTIG / consensus / guidance of $70.5M / $68M / $60M-$70M. HIMS... More